Mankind Pharma aims to clear its ₹13,630-crore debt from acquiring Bharat Serums and Vaccines within three years, according to MD Rajeev Juneja. He was optimistic about using Mankind's reach and marketing skills to expand BSV's range. The successful integration of Panacea in 2022, despite initial doubts, was cited as a positive precedent. Read The Rest at :
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.
